Who are CCB use's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lotrel (amlodipine/benazepril), DHP, losartan/amlodpine, Verapamil Hydrochloride, Phase B: Triplixam / Elestar HCT, Magnesium sulfate IV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ccb-use.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CCB use — Competitive Intelligence Brief

CCB use (CCB use) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

phase 2 Calcium channel blocker L-type calcium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

CCB use (CCB use) — GlaxoSmithKline. CCBs work by inhibiting the L-type calcium channels in the heart and vascular smooth muscle, leading to vasodilation and reduced cardiac workload.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CCB use TARGET	CCB use	GlaxoSmithKline	phase 2	Calcium channel blocker	L-type calcium channels
Lotrel (amlodipine/benazepril)	Lotrel (amlodipine/benazepril)	Abbott	marketed	Calcium channel blocker / ACE inhibitor combination	L-type calcium channels (amlodipine); Angiotensin-converting enzyme (benazepril)
DHP	DHP	Centro de Investigacao em Saude de Manhica	marketed	calcium channel blocker	L-type calcium channels
losartan/amlodpine	losartan/amlodpine	University of Pavia	marketed	Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB)	Angiotensin II receptors (AT1) and L-type calcium channels
Verapamil Hydrochloride	Verapamil Hydrochloride	Pfizer Inc.	marketed	Calcium channel blocker	L-type calcium channels (slow channels)
Phase B: Triplixam / Elestar HCT	Phase B: Triplixam / Elestar HCT	National Institute of Cardiology, Warsaw, Poland	marketed	Fixed-dose combination antihypertensive (calcium channel blocker + ARB + thiazide diuretic)	L-type calcium channels, angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter
Magnesium sulfate IV	Magnesium sulfate IV	University of Liege	marketed	Electrolyte supplement / anticonvulsant	NMDA receptor, L-type calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
Ain Shams University · 1 drug in this class
Bioprojet · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Handok Inc. · 1 drug in this class
Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
Hospital de Clinicas de Porto Alegre · 1 drug in this class
Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CCB use — Competitive Intelligence Brief. https://druglandscape.com/ci/ccb-use. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab